WO2006017325A3 - Aav vector compositions and methods for enhanced expression of immunoglobulins the same - Google Patents

Aav vector compositions and methods for enhanced expression of immunoglobulins the same Download PDF

Info

Publication number
WO2006017325A3
WO2006017325A3 PCT/US2005/024798 US2005024798W WO2006017325A3 WO 2006017325 A3 WO2006017325 A3 WO 2006017325A3 US 2005024798 W US2005024798 W US 2005024798W WO 2006017325 A3 WO2006017325 A3 WO 2006017325A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
same
immunoglobulins
vector constructs
aav vector
Prior art date
Application number
PCT/US2005/024798
Other languages
French (fr)
Other versions
WO2006017325A2 (en
Inventor
Jianmin Fang
Karin Jooss
Original Assignee
Cell Genesys Inc
Jianmin Fang
Karin Jooss
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc, Jianmin Fang, Karin Jooss filed Critical Cell Genesys Inc
Priority to JP2007521594A priority Critical patent/JP2008506389A/en
Priority to EP05770729A priority patent/EP1765846A4/en
Priority to CA002573656A priority patent/CA2573656A1/en
Publication of WO2006017325A2 publication Critical patent/WO2006017325A2/en
Publication of WO2006017325A3 publication Critical patent/WO2006017325A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Single AAV vector constructs for expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The AAV vectors comprise a self-processing cleavage sequence between a first and second immunoglobulin coding sequence allowing for expression of a functional antibody molecule using a single promoter. The vector constructs may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from an expressed immunoglobulin molecule or fragment thereof. The vector constructs find utility in enhanced production of biologically active immunoglobulins or fragments thereof in vitro and in vivo.
PCT/US2005/024798 2004-07-13 2005-07-13 Aav vector compositions and methods for enhanced expression of immunoglobulins the same WO2006017325A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2007521594A JP2008506389A (en) 2004-07-13 2005-07-13 AAV vector composition and method for enhanced expression of immunoglobulin and method of use thereof
EP05770729A EP1765846A4 (en) 2004-07-13 2005-07-13 Aav vector compositions and methods for enhanced expression of immunoglobulins using the same
CA002573656A CA2573656A1 (en) 2004-07-13 2005-07-13 Aav vector compositions and methods for enhanced expression of immunoglobulins using the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58708204P 2004-07-13 2004-07-13
US60/587,082 2004-07-13
US65987105P 2005-03-10 2005-03-10
US60/659,871 2005-03-10

Publications (2)

Publication Number Publication Date
WO2006017325A2 WO2006017325A2 (en) 2006-02-16
WO2006017325A3 true WO2006017325A3 (en) 2006-06-08

Family

ID=35839800

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/024798 WO2006017325A2 (en) 2004-07-13 2005-07-13 Aav vector compositions and methods for enhanced expression of immunoglobulins the same

Country Status (5)

Country Link
US (2) US7714119B2 (en)
EP (1) EP1765846A4 (en)
JP (1) JP2008506389A (en)
CA (1) CA2573656A1 (en)
WO (1) WO2006017325A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK200101581A (en) * 2001-10-26 2003-04-27 Danfoss As Transceiver circuit for ultrasonic flow meter
EP1636360A4 (en) 2003-06-03 2006-11-08 Cell Genesys Inc Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
CA2573656A1 (en) * 2004-07-13 2006-02-16 Cell Genesys, Inc. Aav vector compositions and methods for enhanced expression of immunoglobulins using the same
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
RU2478709C2 (en) * 2005-07-21 2013-04-10 Эбботт Лэборетриз GENE SET EXPRESSION INCLUDING sORF CONSTRUCTS AND METHODS FOR IMMUNOGLOBULIN EXPRESSION
US8129510B2 (en) 2006-03-30 2012-03-06 The Board Of Trustees Of The Leland Stanford Junior University Minigene expression cassette
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
US8298818B2 (en) * 2006-04-28 2012-10-30 University Of Florida Research Foundation, Inc. Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter
US20120183477A1 (en) * 2009-06-26 2012-07-19 Five Prime Therapeutics, Inc. Therapeutic Antibody Target Validation and Screening In Vivo
TWI411681B (en) * 2009-08-18 2013-10-11 Nat Univ Tsing Hua Baculovirus expression vector and application thereof
EP2493923A1 (en) * 2009-10-30 2012-09-05 Abbott Laboratories Sorf constructs and multiple gene expression
ES2887335T3 (en) * 2010-03-17 2021-12-22 Univ Cornell Vaccine against drugs of abuse based on altered adenovirus
EP2678433B1 (en) 2011-02-22 2017-05-03 California Institute of Technology Delivery of proteins using adeno-associated virus (aav) vectors
WO2013130393A1 (en) * 2012-02-28 2013-09-06 Cornell University Aav-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
BR112014024373A2 (en) * 2012-03-30 2017-08-08 Bayer Healthcare Llc protease-regulated antibodies
US10004811B2 (en) * 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
JP7078350B2 (en) * 2013-10-28 2022-05-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア DNA antibody construct and its usage
EA201591131A1 (en) * 2012-12-13 2015-12-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания DNA STRUCTURE ANTIBODY AND METHOD OF THEIR APPLICATION
MX2015011947A (en) 2013-03-14 2015-12-01 Shire Human Genetic Therapies Methods and compositions for delivering mrna coded antibodies.
JP6736464B2 (en) 2013-08-29 2020-08-05 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Cell-permeable conjugates and methods of use thereof
EP3060144A1 (en) * 2013-10-24 2016-08-31 Medgenics Medical Israel, Ltd Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof
SG11201604719WA (en) * 2013-12-13 2016-07-28 Univ Pennsylvania Dna antibody constructs and method of using same
MX2016011690A (en) 2014-03-21 2016-11-07 Univ Leland Stanford Junior Genome editing without nucleases.
JP6974943B2 (en) 2014-05-13 2021-12-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions comprising AAV expressing two antibody constructs and their use
BR112017011556A2 (en) 2014-12-01 2018-03-06 Inovio Pharmaceuticals Inc methods for generating a synthetic antibody, preventing or treating a disease, treating a subject of pathogen infection and a subject with cancer, product, nucleic acid molecule, and composition.
JP6878301B2 (en) * 2015-04-09 2021-05-26 コーネル ユニヴァーシティー Gene therapy to prevent reactions to allergens
CN108136007A (en) * 2015-08-31 2018-06-08 宾夕法尼亚州大学信托人 For treating the chimeric AAV- anti-vegf of dog cancer
EP3727468A4 (en) 2017-12-19 2021-09-22 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
EP3561053A1 (en) 2018-04-26 2019-10-30 Baylor College of Medicine Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy
JP2022513076A (en) 2018-11-19 2022-02-07 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Modular polycistronic vector for CAR and TCR transduction
JP2023521194A (en) * 2020-04-13 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド PSMA and STEAP1 vaccines and their uses
EP4306131A1 (en) 2021-03-08 2024-01-17 Nanjing GenScript Biotech Co., Ltd. Delivery of antibody by using dual viral vector system
CN114107390B (en) * 2021-11-05 2023-10-24 中国科学院精密测量科学与技术创新研究院 rAAV vector for expressing antibody IgG1 and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0623679A1 (en) * 1987-05-21 1994-11-09 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5863765A (en) * 1995-03-03 1999-01-26 Quest International Bv Production in yeasts of stable antibody fragments

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
JPH06501850A (en) 1990-11-09 1994-03-03 ジェネンテク，インコーポレイテッド Retrovirus-like particles in Chinese hamster ovary cells
JP3064465B2 (en) * 1991-03-25 2000-07-12 住友化学工業株式会社 Aromatic compounds, process for producing the same, and pesticides containing the same as active ingredients
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
WO1994016094A2 (en) * 1993-01-12 1994-07-21 Biogen, Inc. Recombinant anti-vla4 antibody molecules
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
GB9326271D0 (en) * 1993-12-23 1994-02-23 Zeneca Ltd Expression of self-processing polyprotein in transgenic plants
US5573500A (en) * 1994-03-24 1996-11-12 Biopit Co., Ltd. Sole massage device
US5525610A (en) 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6133456A (en) * 1994-08-18 2000-10-17 Ariad Gene Therapeutics, Inc. Synthetic multimerizing agents
US6150527A (en) * 1994-08-18 2000-11-21 Ariad Pharmaceuticals, Inc. Synthetic multimerizing agents
US20020168342A1 (en) * 1994-11-03 2002-11-14 Cell Genesys, Inc. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
US6093570A (en) * 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6187757B1 (en) * 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US6040183A (en) * 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6506379B1 (en) * 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
US6306649B1 (en) * 1995-06-27 2001-10-23 Ariad Gene Therapeutics, Inc. Heterologous transcription factors
US5935824A (en) 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US20020168339A1 (en) * 1997-01-20 2002-11-14 Marc Piechaczyk Biological material for treating a mammal by antibody gene transfer and pharmaceutical composition containing same
JP4135120B2 (en) * 1997-04-14 2008-08-20 セル ジェネシス，インコーポレーテッド Method for increasing the efficiency of recombinant AAV production
US6261567B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Overcoming interference in alphavirus immune individuals
US7276488B2 (en) * 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6015709A (en) * 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US6479653B1 (en) * 1997-08-26 2002-11-12 Ariad Gene Therapeutics, Inc. Compositions and method for regulation of transcription
WO1999010510A2 (en) * 1997-08-26 1999-03-04 Ariad Gene Therapeutics, Inc. Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain
US20030099932A1 (en) * 1998-05-12 2003-05-29 Lorens James B. Retroviral vectors with separation sequences
US6933362B1 (en) * 1999-08-17 2005-08-23 Rensselaer Polytechnic Institute Genetic system and self-cleaving inteins derived therefrom, bioseparations and protein purification employing same, and methods for determining critical, generalizable amino acid residues for varying intein activity
US6632800B1 (en) * 1999-08-17 2003-10-14 Mayo Foundation For Medical Education And Research System for monitoring the expression of transgenes
AU776061B2 (en) * 1999-11-15 2004-08-26 Onyx Pharmaceuticals An oncolytic adenovirus
EP1242456B1 (en) * 1999-11-18 2008-10-15 Oxford Biomedica (UK) Limited Scfv antibodies against disease associated molecules
US6911200B2 (en) * 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
ES2172383B1 (en) 2000-04-06 2003-12-16 Univ Madrid Autonoma PROCEDURE FOR THE CONSTRUCTION OF POLICISTRONIC RETROVIRAL VECTORS.
US20040235173A1 (en) * 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
AU2001271614B2 (en) * 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
US20030099616A1 (en) * 2001-07-25 2003-05-29 Irving John M. Dual specificity tumor killing vectors driven by the telomerase promoter
US20040086485A1 (en) * 2001-10-04 2004-05-06 Aguilar-Cordova Carlos Estuardo Chemeric viral vectors for gene therapy
US20040235011A1 (en) * 2002-06-26 2004-11-25 Cooper Richard K. Production of multimeric proteins
US20050095705A1 (en) * 2003-04-15 2005-05-05 Michael Kadan Method for production of oncolytic adenoviruses
WO2004092397A2 (en) * 2003-04-15 2004-10-28 Novartis Ag Tmprss2 regulatory sequences and uses thereof
EP1636360A4 (en) * 2003-06-03 2006-11-08 Cell Genesys Inc Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
CA2573656A1 (en) 2004-07-13 2006-02-16 Cell Genesys, Inc. Aav vector compositions and methods for enhanced expression of immunoglobulins using the same
US20060228336A1 (en) * 2004-10-12 2006-10-12 Derek Ko Human prolyl isomerase 1 (PIN 1) promoter and uses thereof
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
RU2478709C2 (en) * 2005-07-21 2013-04-10 Эбботт Лэборетриз GENE SET EXPRESSION INCLUDING sORF CONSTRUCTS AND METHODS FOR IMMUNOGLOBULIN EXPRESSION
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0623679A1 (en) * 1987-05-21 1994-11-09 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5863765A (en) * 1995-03-03 1999-01-26 Quest International Bv Production in yeasts of stable antibody fragments

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NOEL ET AL.: "High In Vivo Production of a Model Monoclonal Antibody on Adenovital Gene Transfer", HUMAN GENE THERAPY, vol. 13, August 2002 (2002-08-01), pages 1483 - 1493 *
See also references of EP1765846A4 *

Also Published As

Publication number Publication date
EP1765846A4 (en) 2010-02-17
US20060034805A1 (en) 2006-02-16
CA2573656A1 (en) 2006-02-16
WO2006017325A2 (en) 2006-02-16
US7714119B2 (en) 2010-05-11
US20110065779A1 (en) 2011-03-17
EP1765846A2 (en) 2007-03-28
JP2008506389A (en) 2008-03-06

Similar Documents

Publication Publication Date Title
WO2006017325A3 (en) Aav vector compositions and methods for enhanced expression of immunoglobulins the same
WO2004113493A3 (en) Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
WO2007126798A3 (en) Regulated expression of recombinant proteins from adeno-associated viral vectors
WO2007011975A3 (en) Methods to express recombinant proteins from lentiviral vectors
WO2005017149A8 (en) Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
MX348154B (en) IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF.
SI2174946T1 (en) Methods for chemically synthesizing immunoglobulin chimeric proteins
WO2003070760A3 (en) Anti-amyloid beta antibodies and their use
WO2006041934A3 (en) Methods and compositions for improving recombinant protein production
WO2002092771A3 (en) Specific binding proteins and uses thereof
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
AUPR107800A0 (en) Peptide and nucleic acid molecule ii
WO2003020756A3 (en) Hybrid and tandem expression of neisserial proteins
WO1994029350A3 (en) Recombinant disulfide-stabilized polypeptide fragments having binding specificity
UA97473C2 (en) Normal;heading 1;heading 2;heading 3;ANTIBODIES DIRECTED TO HER-3 AND USES THEREOF
WO2004099231A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
WO2002055718A3 (en) Assembly and screening of highly complex and fully human antibody repertoire in yeast
WO2007076162A3 (en) Antimicrobial cathelicidin peptides
UA97628C2 (en) Method For the Mass Production of Immunoglobulin Fc Region Deleted Initial Methionine Residues
WO2006055704A3 (en) Antibodies directed to ten-m proteins and uses thereof
WO2004093808A3 (en) Novel tumor-associated antigens
WO2005049644A3 (en) Tool for the transfer and production of proteins using the pseudomonas type iii secretion system
WO2001047956A3 (en) Method for obtaining proteins having improved functional characteristics
WO2004011605A3 (en) Hybrid protein methods and compositions
WO2005001099A3 (en) Protein expression system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007521594

Country of ref document: JP

Ref document number: 2573656

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005770729

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005770729

Country of ref document: EP